Moreover, the compound has been subjected to clinical trials with codes NCT03070262 and NCT04648917 entitled (The Efficacy and Safety of Caffeic Acid for Esophageal Cancer) and (GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer [ESCC]), respectively. This evidence concerns the gene KDM4C and esophageal cancer.